Antianämika

  • Klaus Mengel

Zusammenfassung

Der größte Teil der Verordnungen von Antianämika entfällt weiterhin auf Eisenpräparate mit einem steigenden Anteil von parenteralen Präparaten und Folsäurekombinationen. An zweiter Stelle folgen die weiterhin rückläufigen Epoetinpräparate und an dritter Stelle Folsäure mit erneut steigenden Verordnungen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Albaramki J, Hodson EM, Craig JC, Webster AC (2012) Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012 Jan 18; 1:CD00785–7Google Scholar
  2. Auerbach M, Ballard H (2010): Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program: 338–347Google Scholar
  3. Baker WF, Bick RL (1999) Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost 25:387–406PubMedCrossRefGoogle Scholar
  4. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. The Lancet 373:1532–1542CrossRefGoogle Scholar
  5. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A et al (NORVIT Trial Investigators) (2006): Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354: 1578–1588Google Scholar
  6. Büchner T (2003) Anämien. In: Therapie Innerer Krankheiten (Hrsg Paumgartner G, Steinbeck G). Springer, Berlin, Heidelberg, New York, S 101–5<NS>10 Aufl</NS>Google Scholar
  7. Curran MP, McCormack PL (2008) Methoxy polyethylene glycol-epeoetin beta: a review of ist use in the management of anaemia associated with chronic kidney disease. Drugs 68:1139–1156PubMedCrossRefGoogle Scholar
  8. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Mcdougall IC et al (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084PubMedCrossRefGoogle Scholar
  9. Dührsen U (2002) Gibt es Indikationen für Erythropoetin in der Onkologie? Dtsch Ärztebl 99:A3470–A3475Google Scholar
  10. European Medicines Agency (2008): Questions and answers on epoetins and risk of tumor growth and blood clots in the vein. Internet: www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500015145.pdfGoogle Scholar
  11. Fishbane S (2003) Safety in iron management. Am J Kidney Dis 41(5 Suppl):18–26PubMedCrossRefGoogle Scholar
  12. Fishbane S, Mittal SK, Maesaka JK (1999) Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney Int 55:67–70CrossRefGoogle Scholar
  13. Food andDAdministration (2007): Information for Healthcare Professionals November 8, 2007. Erythropoesis stimulating agents (ESA). Internet: www.fda.gov/ cder/drug/InfoSheets/HCP/RHE200711HCP.htmGoogle Scholar
  14. Hanley DF (2004) The challenge of stroke prevention. JAMA 291:621–622PubMedCrossRefGoogle Scholar
  15. Heinrich HC (1986) Bioverfügbarkeit und therapeutischer Wert oraler Eisen(II)- und Eisen(III)- Präparate. Dtsch Apoth Ztg 126:681–690Google Scholar
  16. Hermann W, Obeid R (2011) Die obligatorische Folsäurefortifikation von Nahrungsmitteln. Ein in Deutschland kontrovers diskutiertes Thema. Dtsch Ärztebl 108:249–254Google Scholar
  17. Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015–2022CrossRefGoogle Scholar
  18. Hörl WH, Vanrenterghem Y (2005) Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. NephrolDialTransplant 20(3):iii25–i32<NS>Suppl</NS>Google Scholar
  19. Ibbotson T, Goa KL (2001) Darbepoetin alfa. Drugs 61:2097–2104PubMedCrossRefGoogle Scholar
  20. Kaltwasser JP (2003) Eisenmangelanämie. In: Berdel WE, Böhm M, Classen M, Diehl V, Kochsiek K, Schmigel W (Hrsg) Innere Medizin, 5. Aufl. Urban & Fischer, München Jena, S, pp 706–711Google Scholar
  21. Kaltwasser JP, Werner E, Niechzial M (1987) Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneim Forsch 37:122–129Google Scholar
  22. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG et al (1998) Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 339:578–583PubMedCrossRefGoogle Scholar
  23. Koletzko B, Pietrzik K (2004): Gesundheitliche Bedeutung der Folsäurezufuhr. Dtsch Ärztebl 101: A 1670–1681Google Scholar
  24. Lange H, Suryapranata H, De Luca G, Böner C, Dille J, Kallmayer K et al (2004) Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350:2673–2681PubMedCrossRefGoogle Scholar
  25. Lee TW, Kolber MR, Fedorak RN, van Zanten SV (2012) Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis 6:267–275PubMedCrossRefGoogle Scholar
  26. Liu K, Kaffes AJ (2012) Iron deficiency anaemia: a review of diagnosis, investigation and management. Eur J Gastroenterol Hepatol 24:109–116PubMedCrossRefGoogle Scholar
  27. Marsh WA, Rascati KL (1999) Meta-analyses of the effectiveness of erythropoetin for end-stage renal disease and cancer. Clin Ther 21:1443–1455PubMedCrossRefGoogle Scholar
  28. Meerpohl JJ, Schell LK, Rücker G, Motschall E, Fleeman N, Niemeyer CM, Bassler D (2014) Deferasirox for managing transfusional iron overload in people with sickle cell disease. Cochrane Database Syst Rev 2014 May 27; 5:CD00747–7Google Scholar
  29. Nielsen P (2013): Eisen - Pharmakotherapie von Eisenmangel und Eisenüberladung. In: Allgemeine und spezielle Pharmakologie und Toxikologie (Hrsg. Aktories K., Förstermann U, Hofmann F, Starke K). Urban & Fischer Verlag München 11. Auflage, Seiten 711–721Google Scholar
  30. Röhrig G, Doehner W, Schaefer RM, Schulz RJ (2012) Anämie und Eisenmangel in der Geriatrie. Prävalenz, Diagnostik und neue Therapieoptionen. Z Gerontol Geriatr 45:191–196PubMedCrossRefGoogle Scholar
  31. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S et al (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098PubMedCrossRefGoogle Scholar
  32. Steffensen GK, Stergaard O (2011) Administration of the same dose of epoetin-beta intravenously subcutaneously to patients with renal anaemia. Scand J Urol Nephrol 45:461–469PubMedCrossRefGoogle Scholar
  33. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354:1567–1577CrossRefGoogle Scholar
  34. Thomas L, Thomas C, Heimpel H (2005): Neue Parameter zur Diagnostik von Eisenmangelzuständen. Dtsch Ärztebl 102: A 580–586Google Scholar
  35. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012 Dec 12; 12:CD00340–7Google Scholar
  36. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC et al (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarktion, and death: the vitamin intervention for stroke prevention (VISP). JAMA 291:565–575PubMedCrossRefGoogle Scholar
  37. Wald NJ (2004) Folic acid and the prevention of neural-tube defects. N Engl J Med 350:101–103PubMedCrossRefGoogle Scholar
  38. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B (2000) The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin ß: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 15:2014–2019PubMedCrossRefGoogle Scholar
  39. Zhou SJ, Gibson RA, Crowther CA, Makrides M (2009) Should we lower the dose of iron when treating anaemia in pregnancy? A randomized dose-response trial. Eur J Clin Nutr 63:183–190PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Klaus Mengel
    • 1
  1. 1.Mannheim

Personalised recommendations